Drugs / HS-20106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06594965 | Oct 2024 → Oct 2025 overdue | anemia, bone marrow disorder, myelodysplastic syndrome | Hansoh BioMedical R&D Company | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HS-20106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06594965 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06594965 ↗ |